Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live ... CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Mostrar más
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and...
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.51 | 1.7819706499 | 28.62 | 29.25 | 27 | 920660 | 28.31373991 | CS |
| 4 | -5.11 | -14.9240654206 | 34.24 | 36.73 | 27 | 982060 | 30.49378781 | CS |
| 12 | -7.01 | -19.3967902601 | 36.14 | 40.47 | 27 | 594151 | 33.02580161 | CS |
| 26 | -2.01 | -6.45472061657 | 31.14 | 40.47 | 27 | 656596 | 34.67243524 | CS |
| 52 | 0.13 | 0.448275862069 | 29 | 50.23 | 25.77 | 677893 | 35.56027599 | CS |
| 156 | 0.13 | 0.448275862069 | 29 | 50.23 | 25.77 | 677893 | 35.56027599 | CS |
| 260 | 0.13 | 0.448275862069 | 29 | 50.23 | 25.77 | 677893 | 35.56027599 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
